Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Paul Christian Fjeldborg"'
Autor:
Jesper Kjaer, Peter Søe-Jensen, Hamid Tousi, Morten H. Bestle, Morten Steensen, Anne Øberg Lauritsen, Nanna Reiter, Paul Christian Fjeldborg, Lars Hein, Kim M Larsen, Jens D Lundgren, Mads H. Andersen, Zoe Fox, Ditte Strange, Maria Egede Johansen, Jesper Grarup, Thomas Mohr, Klaus J. Thornberg, Jens-Ulrik Stæhr Jensen, Bettina Lundgren, Christian Østergaard, Lene Ryom Nielsen, Katrin Thormar, Jesper Løken, Niels-Erik Drenck
Publikováno v:
BMJ Open
Jensen, J-U S, Hein, L, Lundgren, B, Bestle, M H, Mohr, T T, Andersen, M H, Thornberg, K J, Løken, J, Steensen, M, Fox, Z, Tousi, H, Søe-Jensen, P, Lauritsen, A Ø, Strange, D G, Reiter, N, Thormar, K, Fjeldborg, P C, Larsen, K M, Drenck, N-E, Johansen, M E, Nielsen, L R, Ostergaard, C, Kjær, J B, Grarup, J & Lundgren, J 2012, ' Kidney failure related to broad-spectrum antibiotics in critically ill patients : secondary end point results from a 1200 patient randomised trial ', BMJ Open, vol. 2, no. 2, pp. e000635 . https://doi.org/10.1136/bmjopen-2011-000635
Jensen, J-U S, Hein, L, Lundgren, B, Bestle, M H, Mohr, T T, Andersen, M H, Thornberg, K J, Løken, J, Steensen, M, Fox, Z, Tousi, H, Søe-Jensen, P, Lauritsen, A Ø, Strange, D G, Reiter, N, Thormar, K, Fjeldborg, P C, Larsen, K M, Drenck, N-E, Johansen, M E, Nielsen, L R, Ostergaard, C, Kjær, J B, Grarup, J & Lundgren, J 2012, ' Kidney failure related to broad-spectrum antibiotics in critically ill patients : secondary end point results from a 1200 patient randomised trial ', BMJ Open, vol. 2, no. 2, pp. e000635 . https://doi.org/10.1136/bmjopen-2011-000635
Objectives To explore whether a strategy of more intensive antibiotic therapy leads to emergence or prolongation of renal failure in intensive care patients. Design Secondary analysis from a randomised antibiotic strategy trial (the Procalcitonin And
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38662cd1d0cdf3265f5a44d1fe680802
https://pubmed.ncbi.nlm.nih.gov/22411933
https://pubmed.ncbi.nlm.nih.gov/22411933
Autor:
Thomas Mohr, J Asger Petersen, Christian Østergaard, Morten Steensen, Anne Øberg Lauritsen, Paul Christian Fjeldborg, Lars Hein, Jesper Kjaer, Jesper Løken, Sine Hougaard, Pernille L. Petersen, Peter Søe-Jensen, Søren Hestad, Lasse H. Andersen, Mads H. Andersen, Klaus J. Thornberg, Katrin Thormar, Teit Mantoni, Peder Carl, Morten H. Bestle, Bettina Lundgren, Jens-Ulrik Stæhr Jensen, Bonnie Bømler, Charlotte Dahl Rossau, Hamid Tousi, Carsten B Thomsen, Kim M Larsen, Jesper Grarup, Jens D Lundgren
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 8, Iss 1, p 91 (2008)
Jensen, J-U, Lundgren, B, Hein, L, Mohr, T, Petersen, P L, Andersen, L H, Lauritsen, A O, Hougaard, S, Mantoni, T, Bømler, B, Thornberg, K J, Thormar, K, Løken, J, Steensen, M, Carl, P, Petersen, J A, Tousi, H, Søe-Jensen, P, Bestle, M, Hestad, S, Andersen, M H, Fjeldborg, P, Larsen, K M, Rossau, C D, Thomsen, C B, Ostergaard, C, Kjaer, J, Grarup, J & Lundgren, J D 2008, ' The Procalcitonin And Survival Study (PASS)-a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients ', B M C Infectious Diseases, vol. 8, pp. 91 . https://doi.org/10.1186/1471-2334-8-91
BMC Infectious Diseases, Vol 8, Iss 1, p 91 (2008)
Jensen, J-U, Lundgren, B, Hein, L, Mohr, T, Petersen, P L, Andersen, L H, Lauritsen, A O, Hougaard, S, Mantoni, T, Bømler, B, Thornberg, K J, Thormar, K, Løken, J, Steensen, M, Carl, P, Petersen, J A, Tousi, H, Søe-Jensen, P, Bestle, M, Hestad, S, Andersen, M H, Fjeldborg, P, Larsen, K M, Rossau, C D, Thomsen, C B, Ostergaard, C, Kjaer, J, Grarup, J & Lundgren, J D 2008, ' The Procalcitonin And Survival Study (PASS)-a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients ', B M C Infectious Diseases, vol. 8, pp. 91 . https://doi.org/10.1186/1471-2334-8-91
Background Sepsis and complications to sepsis are major causes of mortality in critically ill patients. Rapid treatment of sepsis is of crucial importance for survival of patients. The infectious status of the critically ill patient is often difficul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a886e45ac1c519be48d084099753484b
https://pubmed.ncbi.nlm.nih.gov/18620598
https://pubmed.ncbi.nlm.nih.gov/18620598